Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyHealthSpring Ranibizumab Coverage Update | OpenPay…
    Ask Trek AI about this page
    ModifiedHealthSpringPolicy OTH903.041

    Ranibizumab Injections, Implants and Biosimilars

    Customize your policy alerts

    Sign up for healthspring Policy OTH903.041 alerts

    Get alerted when Policy OTH903.041 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-necessity coverage for intravitreal ranibizumab products, including Lucentis, biosimilars, and Susvimo administered through the Susvimo ocular implant. It applies to individuals receiving these ophthalmic treatments for specified retinal and ocular conditions.

    Policy Summary
    PayerHealthSpring
    PolicyRanibizumab Injections, Implants and Biosimilars
    Policy CodePolicy OTH903.041
    Change TypeMaterial update
    Effective DateJuly 21, 2026
    Next Review DateN/A
    Key ActionConfirm that Susvimo patients have responded to at least two prior intravitreal vascular endothelial growth factor inhibitor injections and have a covered indication.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added ranibizumab-leyk (Nufymco) as a biosimilar and interchangeable product with Lucentis.

    The policy added ranibizumab-hkdz (Ranluspec) as a biosimilar to Lucentis.

    5Named ranibizumab injection products
    8Standard covered conditions
    2Prior injections required for Susvimo
    3

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Covered Susvimo indications
    All otherNon-FDA-approved indications

    Medical Necessity Coverage Criteria

    Standard intravitreal ranibizumab coverage

    Intravitreal Lucentis or the listed ranibizumab biosimilars may be considered medically necessary when the individual has one of the following conditions.

    Covered standard intravitreal ranibizumab indication

    • Qualifying choroidal neovascularization etiology: Choroidal neovascularization is due to angioid streaks; central serous chorioretinopathy; choroidal retinal neovascularization secondary to pathologic myopia; choroidal retinal neovascularization associated with degenerative progressive high myopia; choroidal rupture or trauma; idiopathic choroidal neovascularization; multifocal choroiditis; pathologic myopia; presumed ocular histoplasmosis syndrome; or uveitis.

      OR logic applies among the listed choroidal neovascularization etiologies.

    Susvimo ocular implant therapy

    Intravitreal Susvimo ranibizumab administered through the Susvimo ocular implant may be considered medically necessary when ALL of the following are met.

    Susvimo medical-necessity criteria: The individual has previously responded to at least two intravitreal injections of a vascular endothelial growth factor inhibitor.At least 2 prior intravitreal vascular endothelial growth factor inhibitor injections with response
    "{"operator":"any","label":"Susvimo covered indication","text":"The individual has neovascular (wet) age-related macular degeneration, diabetic macular edema, or diabetic retinopathy.","note":"OR logic applies among the three listed indications.","children":[]}

    Other non-FDA-approved indications

    The listed ranibizumab products are considered experimental, investigational, and/or unproven for all other non-FDA-approved indications.

    Non-FDA-approved use: The requested product is Lucentis, Susvimo, Byooviz, Cimerli, Nufymco, or Ranluspec and is being used for an indication that is not FDA approved for that product.

    Such use is considered experimental, investigational, and/or unproven.

    Lucentis, Susvimo, Byooviz, Cimerli, Nufymco, and Ranluspec are considered experimental, investigational, and/or unproven when used for any non-FDA-approved indication.

    CPT and HCPCS Coding

    CPT CodesCPT
    67028
    HCPCS CodesHCPCS
    J2778
    J2779
    J3490
    J3590
    Q5124
    Q5128
    Q5168

    Provider Action and Denial Risks

    Denial Risk

    Non-FDA-Approved Indication

    Ranibizumab injections or Susvimo implants used for non-FDA-approved indications are considered experimental, investigational, and/or unproven and may be denied.

    Denial Risk

    Susvimo Eligibility Not Met

    Susvimo may be considered medically necessary only when the individual has previously responded to at least two intravitreal injections of a vascular endothelial growth factor inhibitor and has a qualifying indication. Without both requirements, coverage may be denied.

    • Qualifying indications: neovascular (wet) age-related macular degeneration, diabetic macular edema, or diabetic retinopathy.
    Denial Risk

    Unlisted Diagnosis

    Standard intravitreal ranibizumab may be considered medically necessary only for a covered diagnosis listed in the policy. Requests for an unlisted condition may be denied.

    Clinical Background

    Ranibizumab is an intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy used for retinal vascular and neovascular eye diseases. The policy addresses Lucentis and ranibizumab biosimilars for specified retinal conditions and separately addresses ranibizumab delivered through the Susvimo ocular implant. Susvimo coverage requires a prior response to at least 2 intravitreal VEGF-inhibitor injections and is limited to wet age-related macular degeneration, diabetic macular edema, or diabetic retinopathy.

    Clinical and Policy Definitions

    DME
    AbbreviationDME
    DefinitionDiabetic macular edema
    Policy contextA listed condition for which intravitreal ranibizumab may be medically necessary
    DR
    AbbreviationDR
    DefinitionDiabetic retinopathy
    Policy contextA listed condition for which intravitreal ranibizumab may be medically necessary
    Policy Summary
    PayerHealthSpring
    PolicyRanibizumab Injections, Implants and Biosimilars
    Policy CodePolicy OTH903.041
    Change TypeMaterial update
    Effective DateJuly 21, 2026
    Next Review DateN/A
    Key ActionConfirm that Susvimo patients have responded to at least two prior intravitreal vascular endothelial growth factor inhibitor injections and have a covered indication.
    SourceLink
    On This Page
    Medical Necessity Coverage CriteriaCPT and HCPCS CodingProvider Action and Denial RisksClinical BackgroundClinical and Policy Definitions
    • Covered conditions include diabetic macular edema, diabetic retinopathy, macular edema following CRVO or BRVO, neovascular AMD, neovascular glaucoma, rubeosis, and specified choroidal neovascularization etiologies.
    CRVO
    AbbreviationCRVO
    DefinitionCentral retinal vein occlusion
    Policy contextMacular edema following CRVO is a listed ranibizumab indication
    BRVO
    AbbreviationBRVO
    DefinitionBranch retinal vein occlusion
    Policy contextMacular edema following BRVO is a listed ranibizumab indication
    AMD
    AbbreviationAMD
    DefinitionAge-related macular degeneration
    Policy contextNeovascular (wet) AMD is a listed ranibizumab indication
    CNV/mCNV
    AbbreviationCNV
    DefinitionChoroidal neovascularization
    Related abbreviationmCNV means myopic choroidal neovascularization
    Interchangeable biosimilar
    CimerliRanibizumab-eqrn; a biosimilar to Lucentis
    NufymcoRanibizumab-leyk; a biosimilar to Lucentis
    Relationship to LucentisCimerli and Nufymco are interchangeable with Lucentis for the policy-listed conditions
    CNV
    Clinical definitionAbnormal blood-vessel growth involving the choroidal circulation
    Associated conditionAge-related macular degeneration
    Associated conditionPathologic myopia
    Other associated conditionsCentral serous chorioretinopathy, presumed ocular histoplasmosis syndrome, angioid streaks, idiopathic CNV, uveitis, choroidal rupture, or trauma
    VEGF
    Full termVascular endothelial growth factor
    Ocular roleA mediator implicated in ocular neovascularization and macular edema
    Ranibizumab mechanismRanibizumab binds VEGF-A to inhibit the angiogenesis pathway
    Interchangeable product
    FDA-oriented definitionA biological product approved as highly similar to an FDA-approved reference product
    Clinical similarityThere are no clinically meaningful differences and the product is expected to produce the same clinical result as the reference product
    Switching standardFor repeated administration, switching-related safety or diminished-efficacy risk is not greater than with the reference product alone
    CI; SD
    CIConfidence interval
    SDStandard deviation
    Study reportingBoth abbreviations appear in visual-acuity study results and statistical estimates
    ETDRS-DRSS
    AbbreviationETDRS-DRSS
    Expanded termEarly Treatment Diabetic Retinopathy Study Diabetic Retinopathy Severity Scores
    Study useUsed to report stepwise improvement from baseline in diabetic retinopathy severity
    BCVA
    AbbreviationBCVA
    Expanded termBest Corrected Visual Acuity
    Study useA visual-acuity outcome measure reported in the myopic choroidal neovascularization study
    PDT
    AbbreviationPDT
    Expanded termPhotodynamic therapy
    Study useUsed as the active control in the myopic choroidal neovascularization study
    BCVA
    TermBest Corrected Visual Acuity
    MeasurementMeasured in letters using the ETDRS visual acuity assessment
    Study applicationUsed to assess changes from baseline in the myopic choroidal neovascularization study
    PDT
    TermPhotodynamic therapy
    Role in studyActive control treatment in the myopic choroidal neovascularization study
    Comparator resultThe PDT group had a mean BCVA change of +1.4 letters at Month 3
    Q24W
    AbbreviationQ24W
    Dosing intervalEvery 24 weeks
    Study comparisonThe Susvimo implant delivery interval in the Archway study
    Q4W
    AbbreviationQ4W
    Dosing intervalEvery 4 weeks
    Study comparisonThe intravitreal ranibizumab dosing interval in the Archway study